Navigation Links
Certifications, Presentation of Study Results and Earnings Releases - Research Report on Agilent, Mindray, Bard, Tornier, and Life Technologies
Date:11/11/2013

2 Co-Primary Investigator, presented data related to the study design, demographics, and six-month follow-up results from the patients randomized in the LEVANT 2 Lutonix Drug-Coated Balloon (DCB) trial, at the Transcatheter Cardiovascular Therapies (TCT) conference in San Francisco, California. The Company informed that the follow-up results from randomized patients, treated with the Lutonix DCB demonstrated safety comparable to uncoated balloons (94.0% vs 94.1%) and superior primary patency (92.3% vs 82.7%, p=0.003) by Kaplan-Meier time-to-event analysis. According to Bard, interested parties may access the presentation slides at the Company website, which will be available for a limited time period. The Full Research Report on C.R. Bard, Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/141e_BCR]

--

Tornier N.V. Research Report

On November 5, 2013, Tornier N.V. (Tornier) released its Q3 FY 2013 financial results (period ended September 29, 2013) with revenues of $66.7 million, up 15.1% YoY. Q3 FY 2013 revenue of the Company's extremities product categories totaled $56.9 million, compared to $48.7 million in Q3 FY 2012. Tornier also reported that non-GAAP gross margins improved to 74.2% in Q3 FY 2013 from 73.4% in Q3 FY 2012. Dave Mowry, President and CEO of Tornier, said, "We delivered adjusted EBITDA within our guidance range despite the lower than expected revenue. This was driven by an improvement in non-GAAP gross margin and prudent management of operating expenses. We believe we have the infrastructure in place to support our double-digit constant currency revenue growth and enhanced operating leverage expectations." Tornier stated that for Q4 FY 2013 it expects constant currency
'/>"/>

SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. HeartWare Presentation At The Canaccord Genuity Medical Technology & Diagnostics Forum To Be Webcast
2. ViroPharma Announces Upcoming Data Presentations at the 2013 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting
3. Hologic to Host Investor Presentation at RSNA 2013
4. Thoratec Announces Presentations At Investor Conferences For November 2013
5. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
6. Vital Access Reports Live VWING Clinical Cases and SAVE Study Clinical Data Presentation at CiDA Conference
7. Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013
8. Volcano Announces Upcoming Data Presentations from Large-Scale Studies on Physiology and Imaging Technologies at TCT 2013
9. Healthcare Sector Announced Clinical Data Presentation, Upcoming Financial Release Schedules and Updates on New Drug Applications - Research Report on Alexion, Pacira, pSivida, Momenta and Impax
10. Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting
11. Diabetes Alliance to Feature 17 Presentations for Linagliptin and Investigational Compound Empagliflozin^ During the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... Calif. , July 14, 2014  Mallinckrodt plc (NYSE: ... QCOR ) today announced that the registration statement on ... ("SEC") by Mallinckrodt plc on May 16, 2014 and amended ... of Mallinckrodt and Questcor that also constitutes a prospectus of ... statement on Form S-4 is available on the SEC,s EDGAR ...
(Date:7/14/2014)... 2014 BioAdaptives, Inc. (OTCBB:BDPT) is pleased to ... the roles of President and CEO of the Company.  ... the company that licensed its formulation, intellectual properties, and ... "Mr. Gerald Epling , who ... a privately held entity to a public company, has ...
(Date:7/13/2014)... , July 13, 2014  Eli Lilly ... announced results from its non-clinical study in genetically ... version of the beta-amyloid antibody N3pG and beta-secretase ... therapy was more effective in removing clumps of ... that is thought to lead to Alzheimer,s disease ...
Breaking Medicine Technology:Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 2Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 3Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 4Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 5Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 6Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 7BioAdaptives Prepares for Next Step 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3
... Aug. 5, 2011 Varian Medical Systems, Inc. (NYSE: ... former CEO and member of the Board of Directors for ... of management in global medical device businesses, has been appointed ... Varian,s Board of Directors also increased its size from nine ...
... FOREST, Ill., Aug. 5, 2011 Hospira, Inc. (NYSE: ... today announced U.S. Food and Drug Administration (FDA) approval of ... presentations include 200 mg, 1 gm and 2 gm with ... sales of more than $750 million in 2010, led by ...
Cached Medicine Technology:Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection 2Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection 3
(Date:7/14/2014)... Sunrise, FL (PRWEB) July 14, 2014 ... announced the expansion of its Quality Control and Assurance ... Formulations has hired two additional, highly-qualified quality assurance (QA) ... superior product standards for which IQ Formulations has become ... and QC technicians bring decades of stellar experience and ...
(Date:7/14/2014)... 2014 Secure Decisions, a leading provider ... with the Software Assurance Marketplace (SWAMP) to build a ... that drives everyday life. , The SWAMP, implemented by ... the Morgridge Institute for Research, is funded by the ... security practices by building a free facility with a ...
(Date:7/14/2014)... HealthDay Reporter SUNDAY, July ... a faltering sense of smell might signal the early ... smell test could spot who needs more extensive screening ... ability to identify odors was associated with the loss ... "We,re trying to be able to diagnose Alzheimer,s ...
(Date:7/14/2014)... 14, 2014 Follow ... liquid chromatography or UPLC is a new ... chromatography that involves the use of extremely ... separate chromatographic compounds. This highly sensitive qualitative ... and analysis of chromatography samples. UPLC functions ...
(Date:7/14/2014)... Francisco, California (PRWEB) July 14, 2014 ... expected to reach USD 4,285.1 million by 2020 ... a new study by Grand View Research, Inc. ... computational biology for bioinformatics R&D programs designed for ... increasing number of clinical studies in pharmacogenomics and ...
Breaking Medicine News(10 mins):Health News:Leading Health Supplement Company IQ Formulations Expands Quality Control and Assurance Department 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 3Health News:Need for Faster Sample Analysis Drives Demand for UPLC, According to New Trend Report Published by Global Industry Analysts, Inc. 2Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 2Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 3Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 4Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 5Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 6
... 7- to ... 9-hour flights, HOBOKEN, N.J., Nov. ... Pycnogenol(R), pine bark,extract from the French maritime pine tree, reduces jetlag in ... scan and a,scoring system, showed Pycnogenol(R) lowered symptoms of jetlag such as,fatigue, ...
... N.J., Nov. 5 BD (Becton,Dickinson and Company) (NYSE: ... for the fourth fiscal quarter ended September 30, 2008,representing ... period. This,quarter,s growth rate reflects the favorable impact on ... to account for 5,percentage points of the increase in ...
... Simulation and Education Conference (I/ITSEC) has sold ... County Convention Center in Orlando. Occupying almost 200,000 ... modeling and simulation technology ever. The I/ITSEC ... 2008 at the Orange County Convention Center in ...
... qualified health insurance underwriters, much of the frustration associated with filling ... serve to not only comfort users, but expedite the entire process, ... ... CA (PRWEB) November 5, 2008 -- Internet based insurance agency, TheHealthQuote, ...
... review outlines potential pharmaceutical, dietary, surgical, and other ... among women in the United States, and examines ... risk reduction strategies for women at average risk ... factors. Among the recommendations: aside from following general ...
... six hours of,deliberation, a Broward County Jury awarded a ... secondhand exposure case. Lynda and Michael Daly,claimed that Mrs. ... asbestos-containing brakes manufactured by Ford Motor Co. and,Pneumo Abex. ... was diagnosed in,May of 2007 and has been a ...
Cached Medicine News:Health News:Study Shows Pine Bark Reduces Jetlag 2Health News:Study Shows Pine Bark Reduces Jetlag 3Health News:Study Shows Pine Bark Reduces Jetlag 4Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 2Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 3Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 4Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 5Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 6Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 7Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 8Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 9Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 10Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 11Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 12Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 13Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 14Health News:World's Largest Modeling and Simulation Exhibition Sells Out for '08 2Health News:World's Largest Modeling and Simulation Exhibition Sells Out for '08 3Health News:Customers Now Able to Receive Real Time, Online Assistance during Health Insurance Quote Process 2Health News:Customers Now Able to Receive Real Time, Online Assistance during Health Insurance Quote Process 3
For Canalicular Stenosis. Non-traumatic tip. Silicone tubing swaged into probe. Note: Tubing securely swaged into malleable stainless steel probes. Medical grade silicone. Box of 3, sterile....
For proper plug sizing....
Contour Design Eyelid Implants....
For Frontalis Suspension in patients with significant ptosis and poor levator function....
Medicine Products: